BARUX
Price
$114.80
Change
-$0.52 (-0.45%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

BARUX vs RPTIX

Header iconBARUX vs RPTIX Comparison
Open Charts BARUX vs RPTIXBanner chart's image
Baron Asset R6
Price$114.80
Change-$0.52 (-0.45%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
BARUX vs RPTIX Comparison Chart
Loading...
VS
BARUX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BARUX is a Buy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. BARUX (4.36B). RPTIX pays higher dividends than BARUX: RPTIX (0.18) vs BARUX (0.00). BARUX was incepted earlier than RPTIX: BARUX (9 years) vs RPTIX (9 years). RPTIX is a more actively managed with annual turnover of: 21.70 vs. BARUX (5.48). RPTIX has a lower initial minimum investment than BARUX: RPTIX (500000) vs BARUX (5000000). BARUX annual gain was more profitable for investors over the last year : 18.89 vs. RPTIX (14.81). BARUX return over 5 years is better than : 31.55 vs. RPTIX (15.09).
BARUXRPTIXBARUX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years9 years-
Gain YTD10.4279.127114%
Front LoadN/AN/A-
Min. Initial Investment50000005000001,000%
Min. Initial Investment IRAN/AN/A-
Net Assets4.36B31.4B14%
Annual Yield % from dividends0.000.18-
Returns for 1 year18.8914.81128%
Returns for 3 years-11.43-13.5784%
Returns for 5 years31.5515.09209%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp